Firms looking outside-in deliver competitive edge

Share this article:
A curiosity about competitors is one key to pharma market research that consistently delivers forward-looking insights to brand teams, a new study shows.

Seventy percent of pharma firms interviewed for the study said they incorporate the competitive intelligence (CI) function into their market research, compared to 75% of companies in all industries. CI refers to learning from experiences and best practices of others. By looking at the external market in addition to one’s own brand, a company can benchmark itself against other organizations.

The results of the study were culled from interviews with market research leaders at 85 companies across 20 industries, 36 of them pharma firms. The companies chosen represent high-
performing groups, according to author Best Practices LLC.

Pharma firms are often criticized for being highly decentralized and insular. But as the report finds, an outward-looking culture that turns to market research to help inform all critical decision-making through market, customer and competitor perspectives is a trait shared by many of the respondents.

Other functions finding their way into the professional’s armamentarium include consumer market research (65%) and pricing studies (59%), said research directors at life science firms. This is in addition to the primary and secondary data that form a researcher’s bread and butter.

When building their staff, research managers look for those who can deliver an outside perspective. Market management research was cited as the most important project skill, cited by 89% of research directors, followed by brand-management research skills.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...